Replies to post #73460 on ViaDerma Inc (VDRM)

[gameccks1]

CEO is rarely inclined to properly or promptly inform shareholders, to put it mildly. However, best guess is that it will fall under similar (but currently unannounced) clause like this, from 1Q24 financial report, for countries versus states: "On January 4, 2021, the Company entered into a three-year exclusive distributor and licensing agreement with an affiliate of the Company. The Company provides the FDA registered medication, Tetracyte, to the affiliate’s medical practices in six States. The affiliates created their own private label for the wound care utilizing the Company’s technology." and will be at some as yet, unpublished licensing rate.

[excelsiorvision]

Old news. This was done years ago.

Try emailing Otiko at the wound pros.

[e-mail] for answers about it and see what he has to say.